Recent Updates
Recently added Catalysts
TMDX Negative Sentiment Score: 20/100

TRANSMEDICS GROUP, INC. (NASDAQ: TMDX) INVESTOR ALERT: Investors With Large Losses in TransMedics Group, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: TransMedics Group, Inc. is facing a securities class action lawsuit filed by shareholders who acquired the company's securities between February 28, 2023, and January 10, 2025. The lawsuit claims that the company misrepresented its safety practices and hid critical safety issues. Additionally, it alleges that TransMedics engaged in illegal activities such as kickbacks and fraudulent billing to enhance revenue. Shareholders interested in participating in the lawsuit must act before April 15, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges misrepresentations about unsafe practices by TransMedics.
  • Claims include hidden safety issues, lacking oversight, and using kickbacks.
  • The company is accused of fraudulent overbilling and coercive business tactics.

Full Press Release Details

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, inclusive.
For more information, submit a form at TransMedics Group, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Defendants made misrepresentations concerning TransMedics’ engagement in unsafe practices, the hiding of safety issues and a lack of general safety oversight. In addition, the Company is alleged to have used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the TransMedics Group lawsuit about?

The lawsuit alleges misrepresentations related to safety practices and fraudulent activities.

Who can become a lead plaintiff in the lawsuit?

Any investor from the Class can file papers to become a lead plaintiff by April 15, 2025.

Are there any fees for shareholders in this lawsuit?

All representation is on a contingency fee basis, meaning no fees or expenses for shareholders.

What is Bernstein Liebhard LLP known for?

Bernstein Liebhard LLP has recovered over $3.5 billion for clients and is recognized for its litigation success.

How can I get more information about the lawsuit?

You can submit a form, email investor relations, or call Bernstein Liebhard LLP for details.

Last updated: Feb 19, 2025